Longeveron to Showcase Laromestrocel at Key Longevity Conferences Amid Clinical Progress

  • Longeveron will participate in three longevity/aging investment conferences between October 1-20, 2026.
  • Phase 2b trial results showed laromestrocel improved physical condition in age-related frailty patients.
  • Longeveron received $1M XPRIZE Milestone 2 Award for Healthspan competition.
  • New preprint analysis suggests laromestrocel may reduce neuroinflammation in Alzheimer's disease.

Longeveron's participation in these conferences comes as the company advances its lead candidate, laromestrocel, through multiple clinical stages for aging-related conditions. The recent positive Phase 2b results and XPRIZE award position the company to attract more investment and partnerships in the rapidly growing longevity sector. The new neuroinflammation data adds another potential application area, expanding the therapeutic potential of its stem cell therapy platform.

Clinical Validation
Whether laromestrocel's potential anti-inflammatory effects in Alzheimer's can be confirmed through peer-reviewed research and further clinical trials.
Funding Strategy
How Longeveron will leverage conference participation to secure additional funding for laromestrocel's development in longevity and aging-related conditions.
Regulatory Pathway
The pace at which Longeveron can advance laromestrocel through FDA designations and potential approvals for multiple indications.